Nevertheless, in clinical practice, droxidopa should always be prescribed according to the approved labeling for adult patients with symptomatic nOH caused by primary autonomic failure (PD, MSA, PAF), DβH deficiency, or NDAN. The gene discussed is DBH; the disease is hyperinsulinemic hypoglycemia, familial, 4.